Latest Partnerships News

Emyria has begun treating the first Medibank-funded PTSD patients at its Perth clinic, marking a pioneering step in private insurance coverage for psychedelic-assisted therapy in Australia. This milestone fuels rapid clinic expansion and supports the company’s national rollout strategy.

Scentre Group reported a 3.2% rise in Funds From Operations for H1 2025 and upgraded its full-year distribution guidance, driven by record occupancy and retail sales growth across its Westfield portfolio.

WhiteHawk Limited appoints Giuseppe Porcelli as Chief Strategy Officer to spearhead international growth and strengthen investor confidence, while progressing key U.S. federal cybersecurity contracts.

Estrella Resources and its partner PT Raka Energi Mandiri have agreed to extend key project milestones for their Werumata limestone venture in Timor-Leste, reflecting internal delays but maintaining a positive outlook.

Neurizon Therapeutics reported a $16.6 million loss for FY2025 amid significant progress in its lead neurodegenerative therapy NUZ-001, including regulatory milestones and a global licensing deal. The company is poised to enter a pivotal ALS clinical trial pending FDA clearance.

Lake Resources N.L. has updated its Kachi Phase One DFS Addendum, showcasing improved lithium brine grades, enhanced extraction technology, and stronger project economics, positioning the Kachi lithium project closer to development.

Calix Limited reported solid FY25 results with 17% growth in product revenue, a 23% cut in operating costs, and an extended 18-month cash runway, while progressing key decarbonisation projects.

BlinkLab Limited has expanded its pivotal FDA autism diagnostic trial by partnering with two leading US pediatric institutions, enhancing recruitment and clinical credibility ahead of its 2026 submission.

Calix Limited reported a $20.1 million loss for FY2025 despite an 11.2% increase in revenue, reflecting ongoing investment in its industrial decarbonisation technology platform.

Rhythm Biosciences has completed critical validation of its ColoSTAT colorectal cancer assay and submitted it for ISO15189 accreditation, paving the way for commercialisation. The test demonstrated strong clinical performance, highlighting its potential as a non-invasive diagnostic tool.

Tyro Payments Limited reported FY25 results with strong top-line growth and margin expansion, setting a confident outlook for FY26 backed by AI-driven efficiency and an expanded market.

Chrysos Corporation reported a robust FY25 with 46% revenue growth and an 80% jump in EBITDA, driven by expanding adoption of its PhotonAssay technology and a landmark contract with gold giant Newmont. The company projects further growth in FY26 with revenue guidance of $80-90 million.